The addition of venetoclax to a hypomethylating agent (HMA; decitabine or azacitidine) improved overall survival in AML compared to HMA monotherapy for non-induction candidates. However, data on the relative efficacy of venetoclax combination therapy in adverse-risk molecular groups remains sparse out...
it is not integrated intoRNA[112–114]. 5-aza anddecitabinehave both been approved by the FDA for treatment ofmyelodysplastic syndromes(MDS) andacute myeloid leukemia(AML), as well as inclinical trialsfor other type of cancers (Table 1). However, both 5-aza and decitabine are toxic and hi...
Previous reports of MDS patients treated with intensive chemotherapy [31–33] or decitabine [34] have also observed higher CR rates for patients with RAEB-t compared with other ‘lower-risk’ MDS patients. The shorter OS (9.0 vs 16.6 months; p = 0.021), despite higher CR rates in ...
The classical demethylating agents comprise the analogs of deoxycytidine: 5-azacytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuranosil-5-azacytosine, and dihydro-5-azacytidine. 5-Azacytidine (azacitidine, Vidaza®) and 5-aza-2′deoxycytidine (decitabine, Dacogen®) (Figure 13.1) were develop...
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019,133(1):7-17. [17] Zucenka A, Vaitekenaite V, Maneikis K, et al. Venetoclax-based salvage therapy followed by venetoclax and DLI maintenance vs. FLAG-Ida for...
Calibration standard mixes containing all analytes (AZA, 5-AZA-CdR, C, dC, mC and mdC) were prepared by dilution in CE buffer of the following chemicals: 5-azacytidine and decitabine (Selleckchem, Houston, TX, USA), cytidine triphosphate and deoxycytidine triphosphate (Promega, Madison, WI, ...
95 and a EORTC randomised trial of 10 day decitabine versus 7 + 3 showed similar 4-year overall survival (26% vs 30%) and similar overall transplant success rate (>50% in both arms).96 As perhaps expected, patients older than 70 years treated on the EORTC trial had improved survival ...